James Sulat - Arch Therapeutics Independent Director
| ARTH Stock | USD 1.05 0.13 11.02% |
Director
Mr. James R. Sulat is Independent Director of Arch Therapeutics, Inc. Mr. Sulat served as Chief Executive Officer and Chief Financial Officer of Maxygen Inc., a biopharmaceutical company focused on developing improved versions of protein drugs, from October 2009 to June 2013. Prior to this, he was Chief Executive Officer, Chief Financial Officer and a member of the Board of Directors at Memory Pharmaceuticals Corporationration, which developed innovative drug candidates for the treatment of debilitating central nervous system disorders, from 2005 to 2008. He previously served in senior executive roles for R.R. Donnelley Sons, Co., Chiron Corporationrationration, Stanford Health Services, Inc., and Esprit de Corporationration Inc. He currently serves as Chairman of the Board of Directors of Momenta Pharmaceuticals, Inc., a biotechnology company focused on the analysis, characterization and design of complex pharmaceutical products. He has additionally served on numerous boards including Valneva SE, AMAG Pharmaceuticals, Inc., diaDexus, Inc., and General Surgical Innovations, Inc since 2015.
| Age | 67 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 617 431 2313 |
| Web | https://www.archtherapeutics.com |
Arch Therapeutics Management Efficiency
The company has return on total asset (ROA) of (1.1363) % which means that it has lost $1.1363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (40.148) %, meaning that it created substantial loss on money invested by shareholders. Arch Therapeutics' management efficiency ratios could be used to measure how well Arch Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 14 records | DIRECTOR Age | ||
| Pierre Bastid | Cellectis SA | N/A | |
| JeanMarie Messier | Cellectis SA | N/A | |
| Alain Godard | Cellectis SA | 71 | |
| Herve Hoppenot | Cellectis SA | 58 | |
| Roderick Flower | Antibe Therapeutics | 68 | |
| John Wallace | Antibe Therapeutics | 56 | |
| David Sourdive | Cellectis SA | 56 | |
| Annick Schwebig | Cellectis SA | N/A | |
| Jonathan Goodman | Antibe Therapeutics | 47 | |
| Yung Wu | Antibe Therapeutics | N/A | |
| Amal Khouri | Antibe Therapeutics | N/A | |
| Samira Sakhia | Antibe Therapeutics | N/A | |
| Laurent Arthaud | Cellectis SA | 54 | |
| Rainer Boehm | Cellectis SA | 56 | |
Management Performance
| Return On Equity | -40.15 | |||
| Return On Asset | -1.14 |
Arch Therapeutics Leadership Team
Elected by the shareholders, the Arch Therapeutics' board of directors comprises two types of representatives: Arch Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arch. The board's role is to monitor Arch Therapeutics' management team and ensure that shareholders' interests are well served. Arch Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arch Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Avtar Dhillon, Chairman of the Board | ||
| Punit Dhillon, Independent Director | ||
| Michael Abrams, Chief Officer | ||
| Daniel Yrigoyen, VP Sales | ||
| Terrence MD, Chairman, CoFounder | ||
| James Sulat, Independent Director | ||
| Daniel Wadsworth, Advisor Commercialization | ||
| Terrence Norchi, President CEO, Director | ||
| Steven Kates, VP Technology | ||
| Richard Davis, CFO and Treasurer | ||
| Rutledge EllisBehnke, CoFounder Advisor |
Arch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Arch Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -40.15 | |||
| Return On Asset | -1.14 | |||
| Operating Margin | (364.73) % | |||
| Current Valuation | 12.54 M | |||
| Shares Outstanding | 249.94 M | |||
| Shares Owned By Insiders | 14.58 % | |||
| Price To Earning | (16.36) X | |||
| Price To Book | 34.61 X | |||
| Price To Sales | 638.65 X | |||
| Revenue | 15.65 K |
Pair Trading with Arch Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arch Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arch Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Arch OTC Stock
| 0.88 | MDH | MDH Acquisition Corp | PairCorr |
| 0.88 | WMT | Walmart Financial Report 16th of May 2024 | PairCorr |
| 0.85 | GE | GE Aerospace Earnings Call This Week | PairCorr |
| 0.83 | DIS | Walt Disney Report 8th of May 2024 | PairCorr |
| 0.82 | XOM | Exxon Mobil Corp Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Arch Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arch Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arch Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arch Therapeutics to buy it.
The correlation of Arch Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arch Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arch Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arch Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arch Therapeutics. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Arch OTC Stock analysis
When running Arch Therapeutics' price analysis, check to measure Arch Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Therapeutics is operating at the current time. Most of Arch Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arch Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Therapeutics' price. Additionally, you may evaluate how the addition of Arch Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |